Rapid Tranquillisation

Protocol for the prescribing and administration of injectable drugs for rapid tranquillisation (RT), physical health assessment and monitoring, including prescribing guidelines on the drugs to be used for RT

Clinical Protocol CP11

Protocol Summary Rapid Tranquillisation (RT) with injectable medication refers to the appropriate use of medication to manage violent behaviour safely and effectively. The aim of the intervention is an emergency measure to quickly calm a person down and reduce the risk of further violence and harm to themselves or others rather than treat any underlying mental illness. If an intramuscular (IM) or is prescribed as an alternative route of administration where an individual is refusing the oral drug but they are otherwise not acutely disturbed then this is NOT rapid tranquillisation.

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 1 of 34

Contents

Page 1. Introduction 4

2. Treatment Aims 4

3. Principle Considerations 4

4. Risks Associated with Rapid Tranquillisation 5

5. Circumstances where Special Caution is Required 5

6. Prescribing Rapid Tranquillisation 6

7. Administration of Rapid Tranquillisation 17

8. Post Incident review and Monitoring after Rapid Tranquillisation 19

Appendix 1 - Rapid Tranquillisation Administration Protocol 20 Appendix 2a - Rapid Tranquillisation Prescription and Administration Chart 21 Appendix 2b - Rapid Tranquillisation Monitoring Sheet 22 Appendix 3 - Management of Problems Occurring during Rapid Tranquillisation 23 Appendix 4 - How to use Appendix 5 - Rapid Tranquillisation C36/CP11 – NICE Position Statement

References 30

Acknowledgements 31

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 2 of 34

Document Control Version Date Issued Author / Job Title / Email

1.0 Sept 2010 Samantha Churchward 2.0 May 2012 Forensic services pharmacist [email protected] 3.0 October 2014 4.0 October 2015 5.0 March 2017 6.0 July 2017 James Lee, Clinical Pharmacist, [email protected] 7.0 October 2017 James Lee, Clinical Pharmacist, [email protected] 8.0 October 2018 Samantha Churchward, Forensic services pharmacist [email protected] 9.0 September 2019 Samantha Churchward, Deputy Chief Pharmacist, Medicines Safety and Governance, [email protected] 10.0 December 2019 Emily Riddiford, Clinical Pharmacist [email protected] 11.0 July 2020 Emily Riddiford, Clinical Pharmacist [email protected] 12.0 July 2021 Samantha Churchward, Deputy Chief Pharmacist [email protected] Thea Bull, Meds Opt Nurse Practitioner [email protected] Target audience/ staff groups: Clinical staff: staff responsible for the prescribing, administration and monitoring of rapid tranquillisation therapy Ratifying Group: Drug & Therapeutic Committee Date ratified: July 2021 Implementation date: July 2021 Review date: July 2024

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 3 of 34

Document History Version Start End Author History date date 1.0 Sep 10 SC New Protocol (incorporating C36 Rapid Tranquillisation Policy) 1.1 Mar 12 SC Amendments made to section 7. Changes made to appendices. New statement added to section 2.5. 1.2 May12 SC Updated following feedback from the Drugs and Therapeutics Committee. 2.0 May12 KS Version ratified. 2.0 Oct 13 KS Removed QT interval list (was appendix 3) and replaced with link to new QT doc. 2.0 Mar-14 KS Agreed to extend this guideline to November 2014. An audit is being completed in this area and a review later in the year will coincide with the results for this audit being available. 2.0 Jul14 SC/KS Maximum dose changed from 18mg to 12mg. 2.1 Sep14 SC Protocol reviewed by the Safe and Therapeutic Management of Violence and Group – no changes made as evidence base is still current. Flumazenil Flow Chart added to appendix 4 3.0 Oct14 KS Document ratified at October DTC and signed off. 3.0 Jun15 SC/KS RT Chart updated to prompt physical health monitoring and highlight that a new prescription is required for each episode. 3.1 Sept 15 Oct 15 SC Protocol reviewed in light of the updated NICE guidelines NG10“Violence and aggression: short-term management in mental health, health and community settings” published in May 2015. Requirement for clinical review prior to giving a further dose added. Guidelines updated in line with NICE to include the combined use of with Haloperidol. 3.2 Oct15 Oct15 LO Amendments made to appendix 1 , amendments made to appendix 2.b awaiting confirmation of approval from SC 3.3 Oct15 Oct15 LO Amendment made to appendix 4.0 Oct 15 JBS Document ratified at October DTC and signed off 4.1 Sep 16 SC Section 7.2 ammended 4.2 Mar 17 SC Section 6, 8 and appendix 2 changed to reference new form on CareNotes, plus physical monitoring form removed and replaced with observation table on the reverse of the form. 5.0 Mar 17 JBS Ratified by DTC and signed off

5.1 July 17 Aug 17 SC Treatment guidelines amended to remove 1st, 2nd, 3rd line and include notes on each choice. Table 2 amended to reflect relative risks. 6.0 Aug 17 JBS Ratified at July DTC and signed off 6.1 Sept 17 JL Updated NICE advice and update addition info to include perinatal advice. 7.0 Oct 17 JBS Ratified at October DTC and signed off 7.1 Sep 18 SC Haloperidol doses updated in line with BNF changes from maximum 12mg to 20mg. 8.0 Oct 18 JBS Ratified at October DTC and signed off 8.1 Sept 19 Sept 19 SC Definition of added to p6 section 3 Principal considerations. How to RMS section added to p23 section 8.10 9.0 Sep 19 JBS Ratified at DTC and signed off 9.1 Nov 19 ER Clarified 1 hour gap between IM and IM as per discussion with SC. 10.0 Dec 19 JBS Ratified at DTC and signed off 10.1 Jul 20 ER Statement relating not prescribing dose ranges added to 6.1 as per MOGG and table 1 on page 12. 11.0 Jul 20 JBS Ratified at DTC and signed off 11.1 Jul 21 SC/TB Updated to include Nursing Associates 12.0 Jul 21 JBS Ratified at MSC and signed off

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 4 of 34

1. Introduction

This protocol and accompanying notes must be read in conjunction with the ‘Policy for Rapid Tranquillisation with injectable drugs on Devon Partnership Trust Inpatient Units (C36)’, to support the safe and appropriate use of medication for Rapid Tranquillisation (RT).

The protocol should be followed where RT is considered a suitable clinical intervention, although it is recognised that rigid adherence may not always be appropriate. If it is necessary to prescribe treatment outside these guidelines then this must first be discussed with “an appropriately experienced doctor” and the rationale for this must be clearly recorded in the clinical notes.

“An appropriately experienced doctor” is defined as a doctor who is in possession of MRCPsych or appointment as Consultant, Associate Specialist or ST4-6 doctor within the Trust.

If an intramuscular (IM) antipsychotic or benzodiazepine is prescribed as an alternative route of administration where an individual is refusing the oral drug but they are otherwise not acutely disturbed then this is NOT rapid tranquillisation. The drug in this case should be prescribed on the PRN section of the main drug chart and clearly marked that it is not to be used as part of rapid tranquillisation – there is no need for it to be prescribed on the RT chart or for a Incident report to be completed. It should be noted that for many drugs this would be an unlicensed indication. If there is any doubt whether the prescription falls within the criteria of rapid tranquillisation then it must be treated as rapid tranquillisation and this protocol followed fully.

2. Treatment Aims

The aim of the intervention is an emergency measure to quickly calm a person down and reduce the risk of further violence and harm to themselves or others rather than treat any underlying mental illness The objective is not to induce sleep or unconsciousness, but to promote a calmer state where the individual is still able to participate in further assessment and/ or treatment.

3. Principal Considerations

3.1 Rapid tranquillisation is only one management strategy in the control of disturbed/violent behaviour. Non-drug approaches should be continued throughout rapid tranquillisation. RT should never be used as first line management for aggressive/violent behaviour.

3.2 All medication used in rapid tranquillisation must be given time to work before further medication is administered. A minimum of 1 hour is recommended. Longer intervals are needed for IM olanzapine and (2 hours).

3.3 Intravenous (IV) administration is likely to be extremely hazardous. It cannot be safely administered within the Trust and therefore should not be used.

3.4 Violent behaviour can usually be controlled and managed without the need to use high doses or ‘cocktails’ of medication. The aim of RT is to use the lowest effective dose to promote calmness and reduce the risk of further violence. It is recognised that it is CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 5 of 34

sometimes necessary to exceed the BNF maximum recommended doses, and in situations where this is likely to occur the consultant or duty consultant must be contacted. The Trust protocol on High Dose (CP10) should be followed.

3.5 Rapid Tranquillisation is defined as “chemical restraint” in guidance issued by the Mental Health Services Data Set. Chemical restraint refers to: ‘the use of medication which is prescribed, and administered (whether orally or by ) for the purpose of controlling or subduing disturbed/violent behaviour, where it is not prescribed for the treatment of a formally identified physical or mental illness’. Chemical restraint is a form of restrictive intervention and is required to be incident reported to the national Mental Health Services Data Set see section 8.10 p23.

4. Risks associated with Rapid Tranquillisation

There are specific risks associated with the different classes of medications and when combinations are used the risks are compounded.

Risks include:

 Excessive  Loss of consciousness  Respiratory depression or arrest  Cardiovascular complications and collapse  , and  Neuroleptic malignant syndrome

5. Circumstances where special caution is required

5.1 Separate Treatment Guidelines have been developed for physically frail adults and those with . Physically frail adults are defined as older adults, those with a co-morbid medical condition or those who are .

5.2 General considerations for those who are physically frail:

 ‘Start low & go slow’ with respect to doses of medication prescribed  Absorption and onset of action may be delayed- this must be taken into consideration before administering further doses if initial response to treatment poor  Older people may have a larger volume of distribution, leading to longer duration of action and possible accumulation of medication, therefore increasing risk and duration of adverse effects experienced.

5.3 General considerations for those with dementia:

The use of antipsychotics in people with a diagnosis of dementia is associated with an increased risk of cerebrovascular adverse events and an increased risk of all-cause mortality. For individuals with an organic illness (know or suspected Alzheimer’s dementia, lewy-body dementia ), the use of antipsychotics should generally be avoided, and should only be considered (by or on the recommendation of a consultant psychiatrist) where treatment with alone have been ineffective and where risks associated with RT are considered less than no treatment. CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 6 of 34

5.4 Concurrent physical illness and/ or conditions known to alter :

 renal or hepatic impairment  organic disorder/ or drug intoxication

Consult the current edition of the BNF and / Summary of Product Characteristics for the product to obtain further information.

5.5 Extreme care is needed in the following circumstances:

 congenital prolonged QTc syndromes present  concurrent prescription or use of other medication that lengthens QTc intervals both directly and indirectly (click here). Many psychotropic drugs affect the QTc interval, including antipsychotics, and . This risk may be increased by the co-administration of other drugs also known to affect the QTc interval e.g. anti-arrhythmics, anti-  the presence of disorders affecting metabolism e.g. hypo and hyperthermia, stress and extreme emotions and extreme physical exertion

5.6 Pregnancy: Rapid tranquillisation should be avoided if possible during pregnancy where possible. NICE recommend pregnant woman requiring rapid tranquillisation should be treated according to the standard clinical guidelines on the short term management of violence and aggression (Antenatal and postnatal mental health CG192). NICE also recommend that:

 individuals should not be secluded after rapid tranquillisation  restraint procedures should be adapted to avoid possible harm to the fetus  when choosing an agent for rapid tranquillisation in a pregnant woman, an antipsychotic or a benzodiazepine with a short half-life should be considered; if an antipsychotic is used, it should be at the minimum effective dose because of neonatal ; if a benzodiazepine is used, the risks of floppy baby syndrome should be taken into account (see Table 1 for more info)  during the perinatal period, the woman’s care should be managed in close collaboration with a paediatrician, an anaesthetist and obstetrician

6 Prescribing Rapid Tranquillisation

6.1 Medication for RT must be prescribed on form CP11a ‘Rapid Tranquillisation Prescription and Administration chart’ (see Appendix 2a) AND must be cross referenced on the main ‘Inpatient Prescription and Administration Chart’ in the ‘As required prescriptions’ section, i.e.

Each new episode of rapid tranquillisation requires a new Rapid Tranquillisation CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 7 of 34

Prescription and Administration chart. An episode is defined as the time from which RT is administered until the situation has resolved and the individual requires no further intervention at that time. If the individual at a later date requires further administration of RT then this constitutes another discrete episode of RT and a new RT chart is required. A medical review should take place prior to prescribing RT for a second episode. Only ONE RT chart may be written up for any individual at a time. The reason for prescribing any medication for an acutely disturbed individual must be documented in the individuals’ notes in the Rapid Tranquillisation form on the medication tab on CareNotes.

Dose ranges are not appropriate for rapid tranquilisation. A single dose should be prescribed in accordance with the treatment guidelines in this document, taking into account the individual’s frailty and co-morbidities.

6.2 Situations under which a Prescription for RT may be written

 Planned in anticipation of the individual requiring RT during their admission. This is the preferred way for RT to be prescribed allowing a full consideration of past response to RT and physical health assessment to be completed. The prescription of RT should be kept under regular review and if the individual is no longer likely to require RT then the prescription should be stopped.

 Urgent where RT is required immediately. If an individual deteriorates suddenly or has just been admitted a prescription may be required urgently. It is acknowledged that in this situation a full assessment may not be practical. However all available information should be considered prior to prescribing RT and any contraindications noted. The discretion of the prescribing doctor should be used to determine the safety of prescribing RT in light of the available information.

6.3 Assessment prior to prescribing RT

1. A physical examination should be conducted wherever possible, with particular reference to:

 Parkinson’s Disease, Lewy body dementia, organic syndromes and acute confusional states  General condition and weight  Falls  State of hydration  Infection  Evidence of pre-existing cardiac or pulmonary conditions  Pregnancy  Baseline pulse, blood pressure, temperature and respiratory rate  Head injuries and seizures  Note any illicit drug intoxication, especially alcohol or benzodiazepines, and urine drug screen results where available; the risk of RT may be compounded in people who have recently abused illicit drugs or alcohol  Baseline electrolytes and ECG where recent test results available. ECG monitoring is advisable and wherever possible a baseline ECG should be done

2. Review the notes with regard to person’s medical and medication history including:

/ sensitivities/ severity of EPSEs

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 8 of 34

 Review medication currently prescribed taking note of doses of antipsychotic and benzodiazepines received over the past 48 hours (including the administration of prn medication)  The benefits and adverse effects of previous medication, and previous history of severe extra-pyramidal side effects  Previous response to medication or RT and/or other methods of managing imminent violence

3. Authority under which RT is to be given/Advance directives

 What legal authority is RT being given under? Consideration of the mental capacity act/mental health act must be taken. Further guidance on this can be found in the RT policy C36 (click here to access)  Are any advance directives available?

6.4 Choice of Medication

These treatment guidelines are intended to be used for the majority of people. If it is necessary to prescribe treatment not covered by these guidelines then this must first be discussed with an appropriately experienced doctor.

If an advance directive has been made by the individual or a care plan covering rapid tranquillisation exists this should be considered and adhered to wherever clinically possible.

The individuals’ previous response to medication should always be considered when deciding on the choice of drug or dose to use during rapid tranquillisation. There is a lack of high quality evidence surrounding the drugs used for rapid tranquillisation and their safety. The guidelines were produced using the evidence which is available.

Table 1 below gives a summary of key information for the drugs included in the treatment guidelines and table 2 outlines some of the alternative treatment options which may be considered by “an appropriately experienced doctor”. Please refer to the BNF and product data sheet for more detailed prescribing and administration advice.

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 9 of 34

Treatment Guidelines for Rapid Tranquillisation

If an advance statement has been made by the individual or a care plan covering rapid tranquillisation exists this should be considered and adhered to wherever clinically possible. The individuals’ previous response to medication should always be considered when deciding on the choice of drug and dose to use during rapid tranquillisation. Repeated or prolonged restraint carries significant risks therefore ensuring adequate treatment is essential.

Adults over 16 years – Treatment Options

Notes Guideline Drug Usual Dose Maximum Dose

Benzodiazepines are an 2mg may be repeated 0.12mg/kg/24 appropriate first line after 60 minutes hours Lorazepam IM choice for the majority of (caution respiratory people. depression if more than (Equates to 8mg 2 does given) in a 70kg person)

Used for rather Olanzapine IM than antipsychotic 10mg initially; 5 to properties. Caution if 10mg may be repeated 20mg/24hours Do not give within one hour of an already on antipsychotics IM benzodiazepine. due to risks of high dose after 2 hours antipsychotics.

Caution with Haloperidol Haloperidol 5mg + in cardiovascular disease Promethazine 25mg (pre ECG advised) (50mg may be given if Haloperidol 20mg Haloperidol + Promethazine Combination of the 2 clinically indicated) + Promethazine drugs is more effective IM may be repeated after 1 than haloperidol alone 100mg/24 hours. and is recommended by hour. NICE.

Alternative options for adults over 16 years

The above guidelines are intended to be used for the majority of people, however it is recognised that there are clinical situations where these options may not be suitable. If it is necessary to prescribe treatment outside these guidelines then this must first be discussed with “an appropriately experienced doctor”. It may be necessary to prescribe an alternative treatment or higher dosages in order to effectively treat the individual. Table 2 in the guidelines lists some of the alternatives which may be considered.

Physically Frail Adults over 16 or those with Dementia

Drug Usual Dose Guideline Maximum Dose

1mg may be repeated after 60 minutes (caution Lorazepam IM 0.06mg/kg/24 hours respiratory depression if more than 2 doses given)

Alternative options for physically frail adults or those with dementia

It may be necessary to consider the following treatment options - this must first be discussed with “an appropriately experienced doctor”: • Repeat Lorazepam IM & consider use of ‘adult’ doses (caution with accumulation) • Consider Olanzapine 2.5- 5mg IM or Aripiprazole 5.25mg IM • Consider promethazine IM if lorazepam contra-indicated or for benzodiazepine tolerant person

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 10 of 34

Treatment Guidelines for Rapid Tranquillisation ONLY FOR USE WHEN LORAZEPAM IS UNAVAILABLE If an advance statement has been made by the individual or a care plan covering RTexists this should be considered and adhered to wherever clinically possible. The individuals’ previous response to medication should always be considered when deciding on the choice of drug and dose to use during RT. Repeated or prolonged restraint carries significant risks, therefore ensuring adequate treatment is essential. CAUTION RESPIRATORY DEPRESSION: is associated with a higher risk of respiratory depression than lorazepam. Given the risks a doctor must attend if a second dose of midazolam is required and stay on the ward for an hour after the second dose is given on a unit not co-located with a hospital with an A&E department, advance prescriptions for midazolam must be limited to one dose only before calling a doctor. Adults over 16 years – Treatment Options

Notes Guideline Drug Usual Dose Maximum Dose

Used for sedative rather Olanzapine IM than antipsychotic 10mg initially; 5 to properties. Caution if 10mg may be repeated 20mg/24hours Do not give within one hour of an already on antipsychotics IM benzodiazepine. due to risks of high dose after 2 hours antipsychotics.

Caution with Haloperidol Haloperidol 5mg + in cardiovascular disease Promethazine 25mg (pre ECG advised) (50mg may be given if Haloperidol 20mg Haloperidol + Promethazine Combination of the 2 clinically indicated) may + Promethazine drugs is more effective IM be repeated after 1 than haloperidol alone 100mg/24 hours. and is recommended by hour. NICE.

2nd Line choice only 5mg may be repeated Midazolam IM when Lorazepam is after 1 hour (see 15mg/24 hours unavailable. respiratory depression caution above)

Alternative options for adults over 16years The above guidelines are intended to be used for the majority of people, however it is recognised that there are clinical situations where these options may not be suitable. If it is necessary to prescribe treatment outside these guidelines then this must first be discussed with a doctor who is “an appropriately experienced doctor” It may be necessary to prescribe an alternative treatment or higher dosages in order to effectively treat the individual. Table 2 in the guidelines lists some of the alternatives which may be considered.

Physically Frail Adults over 16 or those with Dementia

Guideline Drug Usual Dose Maximum Dose

Midazolam IM 2.5mg may be repeated after 60 minutes 7.5mg/24 hours

Alternative options for Physically frail adults or those with dementia:

It may be necessary to consider the following treatment options - this must first be discussed with “an appropriately experienced doctor”: • Repeat Midazolam IM & consider use of ‘adult’ doses (Caution with accumulation) • Consider Olanzapine 2.5- 5mg IM or Aripiprazole 5.25mg IM • Consider promethazine IM if lorazepam contra-indicated or for benzodiazepine tolerant person

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 11 of 34

Table 1 - Key Drug Information for Drugs included in the RT Treatment Guidelines Please note that the dose ranges in these tables are only to illustrate the various doses available for use. When prescribing, do not use dose ranges. A single dose should be prescribed in accordance with the treatment guidelines in this document, taking into account the individual’s frailty and co-morbidities. Drug Place in Treatment Administration Cautions and Additional Comments IM Lorazepam Benzodiazepines are relatively safe Dose 1-2mg up to Risks with benzodiazepines include loss of consciousness and respiratory and their effects can be reversed 120mcg/kg/24hrs depression or arrest. with the antagonist flumazenil. Lorazepam injection Flumazenil injection (short acting benzodiazepine antagonist) must be (stored in the fridge) available for benzodiazepine-induced respiratory depression. should be diluted 1:1 with Water for Injection The of lorazepam are the same whether given orally or IM. immediately before IM The only reason to give IM lorazepam is if the person refuses oral. use. Concern is sometimes expressed about the possibility of disinhibition following the administration of benzodiazepines. There is conflicting evidence available about this. It is, however, a rare side effect. Disinhibition maybe more likely to occur in those with organic brain disease, including learning disabilities, the under 18s and the over 65s, and perhaps those with impulse control problems.

Perinatal advice: Greatest risk with use is during first and third trimesters. Use in the first trimester may increase malformation risk in the unborn child and use during third trimester can lead to ‘floppy infant syndrome’ and neonatal withdrawal. General principles would favour shorter-acting preparations (such as lorazepam) and for exposure to be minimised by using the lowest effective dose for as short a time as necessary. IM Olanzapine Where benzodiazepines are not Dose: 5-10mg (usual IM olanzapine has been shown in a number of studies to be at least as considered to be appropriate, such dose 10mg) followed by effective, and overall more effective than IM haloperidol with significantly less as for individuals who are tolerant to 5-10mg after 2 hours if extrapyramidal side effects or risk of QT prolongation and may have a faster benzodiazepines or where necessary up to 20mg in onset of action. benzodiazepines have been 24 hours (maximum ineffective in the past. It should be combined oral and IM) If the person is considered to need IM benzodiazepine treatment, this noted that antipsychotics used during Maximum 3 injections in should not be given until at least one hour after IM olanzapine CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 12 of 34

Drug Place in Treatment Administration Cautions and Additional Comments rapid tranquillisation are used for 24 hours for 3 days administration. If the person has received IM benzodiazepine, IM their sedative rather than olanzapine administration should only be considered after careful evaluation antipsychotic properties. of clinical status, and the person should be closely monitored for excessive sedation and cardiorespiratory depression.

IM olanzapine may produce a 5-fold increase in plasma concentration compared to the same dose given by the oral route.

Olanzapine IM is a black triangle drug▼: Please report ALL adverse reactions observed using the Yellow card system or the MHRA website.

Perinatal advice: If an atypical is preferred in a patient with a known predisposition to extra- pyramidal side-effects, or if there is previous evidence of treatment response to either olanzapine or , these may be suitable options instead. If an IM atypical is required, aripiprazole may be considered. Olanzapine may increase the risk of hyperglycaemia and fetal growth, although evidence for this is conflicting. Use of antipsychotics in pregnancy has been associated with neonatal withdrawal and EPSEs. IM Haloperidol+ It is recommended that this is not Dose: IM haloperidol is no longer recommended first line for rapid tranquillisation promethazine. used unless a pre-treatment ECG is due to: available and the person has had a Haloperidol 5mg up to a  High incidence of acute previous history of a good response maximum of 20mg in 24  Requirement for a pre-treatment ECG to haloperidol and has tolerated it hours. well. There may however be Haloperidol and lorazepam IM should no longer be used routinely in situations where other treatment Promethazine 25 -50mg combination. The data sheet for lorazepam IM states that there have been options have failed and based on an up to a maximum of reports of apnoea, coma, bradycardia, heart arrest and death with the assessment of the risks/benefits to 100mg/24 hours. concomitant use of lorazepam injection solution and haloperidol. the individual haloperidol IM is given despite these recommendations not injection must be available. It is recommended that it is being met – the reason for prescribed with IM haloperidol to reduce the risk of dystonia/other EPSEs. proceeding with haloperidol in these circumstances should be clearly The of IM haloperidol is 50% greater that oral haloperidol. CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 13 of 34

Drug Place in Treatment Administration Cautions and Additional Comments documented in the individual’s notes. Prescriptions for oral and IM medication must be written separately (not PO/IM). NICE CG10 recommends the combination of haloperidol with Promethazine is contraindicated in people with central nervous system promethazine – The Trust guidelines depression and those who have taken monoamine oxidase inhibitors within have been updated in accordance the past 14 days. Cautions include respiratory conditions, coronary artery with this. When IM haloperidol is disease, epilepsy and hepatic and renal insufficiency. Adverse effects include combined with IM promethazine drowsiness, dizziness, restlessness, , nightmares, tiredness, there is some suggestion that risk of disorientation and effects. movement-related side effects may be reduced. Promethazine and haloperidol must not be mixed in the same syringe but given as separate injections.

Perinatal advice: Haloperidol is the antipsychotic of choice due to there being more experience of its use during pregnancy compared to the newer agents. If extra-pyramidal side-effects develop, switching to an atypical may be preferable to exposure to additional anti-muscarinic medicine. Use of antipsychotics in pregnancy has been associated with neonatal withdrawal and EPSEs. Midazolam 2nd Line only when Lorazepam is In reported trials, the Like other benzodiazepines midazolam has the potential to cause respiratory unavailable. dose used has ranged depression but this risk is thought to be greater than with lorazepam. Always from 2.5mg to 15mg, ensure that emergency resuscitation equipment and medication (including although it must be noted flumazenil) is present before administration. Remember midazolam acts that the higher doses for a longer period than flumazanil - additional doses may be required. appear to induce sleep, whereas the aim of rapid Following IM Midazolam, anterograde amnesia of short duration may occur tranquilisation is to with the individual not remembering events that occurred during the promote a calmer state maximum activity of the compound. and not induce sleep/unconsciousness. Midazolam is now a schedule 3 controlled drug, therefore must be ordered The recommended dose from the pharmacy department using the ward controlled drug requisition in the Trust Guidelines is book in accordance with Trust standard operating procedure CD1. Once 5mg for adults over 16 received, midazolam injection should be recorded in the controlled drugs years and 1 to 2.5mg for register and stored in the controlled drugs cupboard. CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 14 of 34

Drug Place in Treatment Administration Cautions and Additional Comments physically frail adults. The NPSA issued an alert on reducing risk of overdose with midazolam Only the 10mg/5ml injection in adults. strength should be Link:http://www.nrls.npsa.nhs.uk/resources/?entryid45=59896. stocked for rapid The strength of midazolam injection recommended in this Guidelines is tranquillisation on classed by the NPSA as being high strength. However the volume required inpatient wards: of the lower strength preparation to allow the doses needed for rapid tranquillisation would be too large. To minimise the risk of errors in dosing occurring only the 10mg/5ml strength should be stocked for rapid tranquillisation on inpatient wards.

If in exceptional circumstances there is a clinical need for a different strength of midazolam injection to be kept on a ward then an individual risk assessment should be done and all possible steps taken to avoid any confusion between the different strengths.

Please note Midazolam injection is in section 15.1.4 of the BNF rather than section 4 therefore existing T2/T3 forms will need to be updated to allow midazolam to be given instead of lorazepam.

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 15 of 34

Table 2 - Other Treatment Options (must be discussed with “an appropriately experienced doctor” prior to prescribing)

Drug Place in Treatment Administration Cautions and Additional Comments IM Haloperidol + May be appropriate where an individual See above under See above under individual drugs for specific cautions. IM Lorazepam has responded well to this combination in individual drugs for It has been common for combinations of benzodiazepines and the past or has failed to respond to the doses antipsychotics to be used. Previous guidelines have advocated this drugs given alone. The warning in the approach. In people where antipsychotics are considered product data sheet regarding the necessary this practice is thought to be beneficial because it potential risks of combing the 2 drugs reduces the dose of the antipsychotic that is required. It has been must be taken into consideration. suggested that the two classes of drug have a synergistic action. Due to the risks of combining benzodiazepines and antipsychotics it is now recommended that this approach is avoided. The data sheet for lorazepam IM states that there have been reports of apnoea, coma, bradycardia, heart arrest and death with the concomitant use of lorazepam injection solution and haloperidol. The haloperidol warning was added following a review of adverse event reports worldwide by Wyeth Pharmaceuticals. It should be noted that the risk of this is low when considered in the context of the large number of people who have been treated with this combination. The individual should be monitored closely where this combination is given. Caution is required in the use of Haloperidol in Cardiovascular disease. It is recommended that a pre treatment ECG is done before the use of Haloperidol. IM Aripiprazole An alternative antipsychotic treatment Dose: 5.25 -15mg IM aripiprazole was licensed in the UK in 2008. It has been shown option to olanzapine IM. (usual dose 9.75mg) in some clinical trials to be as effective as haloperidol, but there followed by 5.25 - are no head-to-head comparisons with olanzapine at present. 15mg after 2 hours if Overall trial data suggests that it is less effective than olanzapine necessary up to 30mg or haloperidol. in 24 hours (maximum combined oral and IM) Aripiprazole IM is a black triangle drug▼: Please report ALL adverse reactions observed using the Yellow card system or the Maximum 3 injections MHRA website. in 24 hours. Perinatal advice: CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 16 of 34

Drug Place in Treatment Administration Cautions and Additional Comments If an atypical is preferred in a patient with a known predisposition to extra-pyramidal side-effects, or if there is previous evidence of treatment response to either olanzapine or risperidone, these may be suitable options instead. If an IM atypical is required, aripiprazole may be considered. Use of antipsychotics in pregnancy has been associated with neonatal withdrawal and EPSEs. IM Aripiprazole + IM aripiprazole and IM lorazepam can be See above under See above under individual drugs for specific cautions. IM Lorazepam administered at the same time however individual drugs for If Aripiprazole and lorazepam are co-administered monitor blood the risk of orthostatic is doses. pressure closely as the risk of is increased. increased.

IM Promethazine This is an which may be Dose: 50mg may be This antihistamine has a slow onset of action, but is often an used as an alternative to repeated up to a effective sedative especially when individuals are regularly benzodiazepines or antipsychotics, maximum of 100mg in prescribed or abuse benzodiazepines. Wait 1-2 hours after the although it has a slow onset of action. 24hours. injection to assess the response. Promethazine IM is NOT licensed for use in rapid tranquillisation. Dilution is not required before IM Perinatal advice: administration. Studies do not suggest an association between in utero promethazine exposure and increased risks of congenital malformation, preterm delivery, low birth weight or adverse neurodevelopmental outcome. Neonatal monitoring may be necessary where antenatal exposure has occurred close to delivery due to possibility of side effects and neonatal withdrawal.

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 17 of 34

Adjuncts to RT

Zuclopenthixol acetate (Clopixol Acuphase): acetate is not considered as part of rapid tranquillisation due to its long onset and duration of action. However there are individual cases where its use may be considered as an adjunct to RT. See Prescribing Guideline (PG21) which contains information on the safe and appropriate use of this medicine. Please note Zuclopenthixol acetate should be prescribed on the main prescription chart NOT on an RT chart.

The following treatments are NOT recommended for rapid tranquillisation within the Trust:

1. IM/IV : Chlorpromazine is particularly dangerous when administered IM. IM chlorpromazine should not be used under any circumstances.

2. IM : Diazepam should not be administered intramuscularly due to slow and erratic absorption, leading to an unpredictable response.

3. IV Diazepam: The IV administration of diazepam is extremely hazardous and given the lack of adequate medical support to give IV diazepam safely within the Trust it should not be used.

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 18 of 34

7. Administration of Rapid Tranquillisation Rapid Tranquilisation is not within the scope of practice of the Nursing Associate

7.1 Prior to administering RT consider:

 Have alternative approaches to RT been considered such as verbal de-escalation? Continue to use non-drug approaches throughout rapid tranquillisation  Has oral medication been offered? If an individual will take oral medication this should be used instead of RT  Facilities for resuscitation must be available.  The following medication must be available in case of emergencies to treat complications: o Procyclidine injection o Flumazenil injection (doctor only)  What other medication has the individual received in the past 24 hours? If they have already received benzodiazepines or antipsychotics via any route then will the administration of RT exceed the BNF maximum dose, if so than a doctor should be contacted prior to administration.  The individual’s physical state – There may be physical reasons for the individual’s distress such as infection which can be treated. If the individual is physically unwell or intoxicated it may be unsafe to administer RT therefore a doctor should be contacted prior to administration.  Consideration should be given to the risks of not proceeding with RT versus the risks of going ahead with RT.Clinical judgement is important in weighing up the decision to proceed with RT in any situations where there is a risk to the individual or others if RT isn’t given.  What legal authority is RT being given under? Consideration of the mental capacity act/mental health act must be taken. If RT is given without the appropriate legal authority then it will constitute an assault on the individual and legal action may be taken against the person administering the drug. Always check that you have the legal authority to administer the drug, if in doubt contact “an appropriately experienced doctor” prior to administering RT. Further guidance on this can be found in the RT policy C36  The Medusa website may be useful to obtain information and advice on administering injectable drugs. Click here to access (login details can be obtained by contacting the medicines optimisation team).

7.2 Administering RT

Once the decision has been made to proceed with RT, the RT administration protocol (Appendix 1) should be followed and administered as per the RT prescription.

Use the rapid tranquillisation chart (Appendix 2) to record the administration and record all mandatory physical monitoring on the reverse. A record of the administration must also be made on the main drug chart in the PRN section as follows:

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 19 of 34

Before giving further doses of rapid tranquillisation a clinical review is required to ensure the safety of proceeding. The nurse in charge should contact a member of the medical team prior to giving further doses of rapid tranquillisation. The medic must confirm that physical health monitoring/observation has been completed appropriately and that the results of this support further doses IM medication to be safely given – this does not necessitate a physical review in person but the medic must assure themselves that they have sufficient information to allow a further dose of IM medication to be given. If there are any concerns regarding the safety to precede a full medical review should be completed prior to administering further doses of IM medication. In certain situations the risk of provoking further violent behaviour/ assault by imposing physical observations will need to be balanced against the risks of not carrying out these checks. If it is not possible to carry out regular physical observations, due to the person’s level of disturbance, then 15 minute visual observations should be maintained and recorded, until physical observations become possible and a decision to proceed made on the basis of this.

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 20 of 34

7.3 Required monitoring post-administration of IM medication for RT

It is important that the following monitoring is completed for all individuals who are administered an for RT, this is because high stress levels, hyper- aroused physical state, restraint, agitation and hypokalaemia can all place the person at high risk of developing cardiac arrhythmias, in addition to other known adverse effects associated with prescribing medication indicated for RT. The mandatory observations must be recorded in the individual’s clinical record.

Time

*

elapsed

post

rate

(BP)

Pulse

ydration

(Pulse (Pulse injection (LOC)

Level of of Level

Dystonic Dystonic

reactions

oximeter)

H

fluidtaken) (minutes) Respiratory

Temperature

O2 saturation O2

(fluid offered & offered (fluid

consciousness consciousness pressure Blood 15    Monitor  continuously 30      if sleeping /   unconscious 45    OR if signs  of cyanosis develop 60       

Continue to repeat all monitoring once every 30 minutes until person is alert and responsive, 60+ or for at least 4 hours (which ever is longer)

* Key for recording level of consciousness (LOC) 1) awake & active 2) awake & calm 3) asleep but arousable 4) unconscious & not arousable

A sedated or unconscious person must have a nurse with him/ her at all times until they are alert and responsive. This may be at a level 3 (within eyesight) and not necessarily at level 4 arms . Even if someone appears sedated or just asleep, it is important to keep a safe distance until you can assess that person’s mental state on their wakening.

If a person is unconscious and not arousable request an immediate review of physical state by a medical doctor.

Once alert and responsive, continue to monitor alertness, mental state and behaviour. Re-start physical observations if any concerns identified.

Non-contact observations: In certain situations the risk of provoking further violent behaviour/ assault by imposing physical observations will need to be balanced against the risks of not carrying out these checks. If it is not possible to carry out regular physical observations, due to the person’s level of disturbance, this must be clearly stated in the clinical notes, then 15 minute visual observations should be maintained and recorded, until physical observations become possible.

The table in Appendix 3 gives advice on the management of problems occurring during RT.

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 21 of 34

8. Post RT Debrief and Monitoring Required after Rapid Tranquillisation

8.1 An incident report must be completed for the RT episode. The Incident number must be recorded on the top of the completed RT prescription chart and this scanned onto Electronic Record System. See below 8.10 for how to record on RMS.

8.2 Once the episode has finished at the earliest opportunity a documented discussion of the RT episode by the clinical team should take place including response to treatment and side effects, so that this can inform future treatment. This should involve the individual (and parents/ guardians/ carers) where possible. The discussion should be documented on the Rapid Tranquillisation form in the medication tab of CareNotes. Care plans should be updated to reflect future plans for RT in light of response to current episode.

8.3 The individual should be reviewed by a doctor at the earliest opportunity, but within 24 hours of receiving RT. A new RT prescription chart should be written up if required and appropriate for the individual – this should be done taking into account their response to RT and side effects experienced. A new Rapid Tranquillisation form must be created on CareNotes in the medication tab –information on the debrief and outcomes will be pulled forward into the new form.

8.4 Regularly prescribed medication should be reviewed: start, restart or change medication where clinically indicated. Review any ‘when required’ medication. A new RT prescription should be completed if clinically appropriate.

8.5 Consider conducting an ECG following the administration of antipsychotics if the following apply:

 high doses are used,  when used in combination with any other medication known to prolong the QTc interval (click here)  if the baseline ECG is abnormal or a baseline ECG wasn’t available  if there is any clinical indication to repeat the ECG.

8.6 Monitor electrolytes if not checked in the last 3-4 days.

8.7 Following any intervention for the acute management of disturbed behaviour, the individual involved must be given the opportunity to talk to a member of staff about the incident. Every effort must be made to establish whether the individual understands why this happened. This must be documented in the individual’s notes on the Rapid Tranquillisation form in the medication tab.

8.8 The individual must be offered the opportunity to write an account of their experience which should be uploaded onto the Electronic Record System. The individual may wish to dictate this to a member of staff to document if they are unable or unhappy to write it themselves. This is optional, but should be encouraged.

8.9 Any post incident learning and or follow up actions should be captured within ‘actions’ function of RMS and followed up via that route.

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 22 of 34

8.10 How to Record on RMS The use of chemical restraint must be recorded as on RMS. This is done in the following way (see also screenshots) 1. Enter the details of the incident on the first page. 2. On the second page select the following in response to the questions. 3. Was Restraint/chemical restraint/segregation or seclusion used? Answer YES 4. Add Intervention? List All Used Select from the list: SELECT “Rapid Tranquillisation IM”

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 23 of 34

Appendix 1 RAPID TRANQUILLISATION ADMINISTRATION PROTOCOL Check medication administered in previous 24 hours to ensure BNF limits not exceeded without advice from an appropriately experienced doctor. Consider and appropriately treat other medical conditions such as acute infection, intoxication, delirium, discomfort, pain, side effects from other medication (e.g. akathisia). Consider past response to Rapid Tranquillisation (RT).

Is oral medication unsuccessful? Consider OR alternative Is medication refused? NO intervention(s) OR before proceeding Is there a serious risk to person to RT

T from restraint? N E D

I YES C

N Complete ‘Before Administration’ section of prescription chart I Administer IM medication according to prescription chart E (see treatment guidelines for specific information, where 2 H

T drugs are being given together they should not be mixed in the

T same syringe). U

O Monitor for response and adverse side effects. H Nursing and medical team to review. G After a period of at least 60 minutes, is response to treatment U positive? O

R NO H T

S What is the type E of response? H C

A PARTIAL RESPONSE NO RESPONSE O

R Repeat dose (A member of the Consider giving an alternative

P medical team must verbally confirm medication (A member of the P that it is safe to give a further dose of medical team must verbally confirm A NO IM medication based on clinical that it is safe to give a further dose of YES G safety. - Olanzapine may only be IM medication based on clinical N U repeated after 2 hours). safety). O R N D

- E S

U Monitor for response and adverse side effects.

Nursing and medical team to review. O YES

T After a period of at least 60 minutes, is response to treatment

E positive? U

N NO I T

N Have 3 separate doses of IM medication been administered? O AND / OR C Has maximum BNF recommended daily dose of medication(s) been reached / exceeded?

YES

Plan for the 24 hours after Seek urgent advice from a doctor successful RT who is a member of the Royal College of Review physical health status and Psychiatrists who may consider specialist continue physical monitoring. treatment options. Doctor to review person within Contact a Medicines Management Pharmacist to 24hr and write new RT chart if discuss treatment options where required. appropriate Complete a Incident Report. Complete a Incident Report.

Required monitoring post-administration of IM medication for Rapid Tranquillisation Time elapsed Temp Pulse Blood Resp. Level of O2 saturation Dystonic Hydration post injection pressure Rate consciousness (Pulse oximeter) reactions (fluid offered & taken) 15 mins    Monitor  continuously if 30 mins      sleeping/   unconscious OR 45 mins    if signs of  cyanosis 60 mins      develop   Continue to repeat all monitoring once every 30 minutes until person is alert and responsive, or for at least 4 hours (which 60 mins + ever is longer) A sedated or unconscious person must have a nurse with him / her at all times until they are alert and responsive.

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 24 of 34

Appendix 2a Rapid Tranquillisation Prescription and Administration Chart A new chart must be written for each separate episode of rapid tranquillisation Prescriber must complete a rapid tranquillisation rationale form on CareNotes [Tick]

SURNAME: FIRST NAME:

NHS No. WARD DOB CONSULTANT

Physical health risk factors?

Allergies/sensitivities?

Must be completed before administering: (by nursing staff) Other antipsychotics or benzodiazepines received in past 24 hrs? Please specify Has oral medication been offered? Yes/No Authority under which RT is being given? (e.g. Mental Capacity act, Mental Health Act: 3 month rule, T3,or section 62) Prescription (for ONE episode of rapid tranquillisation ONLY) Drug name: Route: Dose: Min. Dose Max dose in 24 IM Interval: hrs: Additional instructions: (refer to guidelines) THIS FORM IS INCLUDED IN THIS CLINICAL Prescriber’s signature: PROTOCOL FOR INFORMATION ONLYDate:

Prescriber’s name and contactTO number: OBTAIN A COPY OF THIS FORM, PLEASEPharmacy: DOWNLOAD CP11a FROM THE MEDICINESForm completed on CareNotes Tick Administration record: MANAGEMENT SECTION OF THE DEVON Date Time PARTNERSHIP TRUSTDose INTRANET Given by

CLICK HERE TO ACCESS Prior to 2nd Dose: Has a member of the medical team confirmed that a further dose may be safely given? [Tick]

Drug name: Route: Dose: Min. Dose Interval: Max dose in 24 IM hrs: Additional instructions: (refer to guidelines)

Prescriber’s signature: Date:

Prescriber’s name and contact number: Pharmacy:

Administration record: Date Time Dose Given by

Prior to 2nd Dose: Has a member of the medical team confirmed that a further dose may be safely given? [Tick]

Ensure physical health monitoring is completed as per the table on the reverse Debrief /outcome of episode must be completed on CareNotes Rapid Tranquillisation form

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 25 of 34

Appendix 2b

Rapid Tranquillisation Physical Health Monitoring:

Time )

*

elapsed

post

rate

(BP)

Pulse

(Pulse (Pulse injection (LOC)

Level of of Level

Dystonic Dystonic

reactions

oximeter

Hydration

fluidtaken) (minutes) Respiratory

Temperature

O2 saturation O2

(fluid offered & offered (fluid

consciousness consciousness pressure Blood 15    Monitor  continuously 30      if sleeping /   unconscious 45    OR if signs  of cyanosis develop 60       

Continue to repeat all monitoring once every 30 minutes until person is alert and responsive, 60+ or for at least 4 hours (whichever is longer)

* Key for recording level of consciousness (LOC) 1) awake & active 2) awake & calm 3) asleep but arousable 4) unconscious & not arousable

Physical health monitoring has been recorded as part of the clinical records on the appropriate monitoring form. Tick Please document where physical monitoring has been recorded

If it is NOT possible to safely monitor physical health following rapid tranquillisation due to the level of disturbance, confirm that the person is alert and responsive. (Non- contact Observations) Tick

15 minute visual observations must be maintained and recorded, until physical observations become possible.

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 26 of 34

Appendix 3

Management of Problems Occurring During Rapid Tranquillisation

Problem Remedial Measures Acute dystonias (including oculogyric Procyclidine 5 – 10 mg IM (repeat after 20 minutes if crisis) and (see also necessary) or IV (repeat after 10 minutes if necessary) below) Older adults: 2.5 – 5mg Increased temperature or marked . Withhold antipsychotics muscular rigidity . Monitor closely - send bloods for CPK level (risk of Neuroleptic Malignant Syndrome . Cool the person and perhaps arrhythmias) . Seek urgent medical advice immediately AND refer to ITU if continued or any other signs of NMS, such as sweating, or fluctuating BP, , incontinence/retention/obstruction, muscular rigidity (may be confined to head and neck) or confusion, agitation/altered consciousness.

Oxygen and flumazenil (a benzodiazepine antagonist) may Respiratory depression: be given if benzodiazepine-induced respiratory depression.

Flumazenil may only be administered by a DOCTOR only who, in their professional opinion are competent to use it respiratory rate <10/minute after safely. There is no expectation for other medical staff of any lorazepam or if oxygen saturation <90%) grade or any other clinician to use it. There are risks associated with the use of flumazenil it should only be used in life threatening situations.

See flow chart below in Appendix 4 for how to give Flumazanil.

If induced by other agent, person will require mechanical ventilation – arrange transfer to an ITU immediately.

Irregular/slow (<50/min) pulse Monitor closely and refer to specialist medical care immediately Hypotension Lie person flat, raise legs if possible Fall in blood pressure Monitor closely (Orthostatic or <50mmHg diastolic)

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 27 of 34

Appendix 4 How to use Flumazenil Flowchart describing the use of i/v flumazenil in the event of respiratory depression associated with benzodiazepines given as part of the Rapid Tranquillisation Protocol:

To only be administered by a DOCTOR who, in their professional opinion, are competent to use it safely. There is no expectation for other medical staff of any grade or any other clinician to use it. There are risks associated with the use of flumazenil it should only be used in life threatening situations.

If, after the administration of benzodiazepines, the individual appears to go into respiratory depression and respiration falls below 10 /minute:

Call the emergency services. Give Flumazenil 200micrograms I/V over 15 seconds

If required level of consciousness is not obtained, after 60 seconds, give another Flumazenil 100micrograms I/V over 10 seconds

Repeat process until consciousness is achieved (maximum of 7 further cycles, i.e. a maximum dose of flumazenil of 1mg/24 hours)

Notes

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 28 of 34

 This is only part of the initial stage of managing respiratory depression induced by benzodiazepines. The individual must be transferred immediately to an acute medical hospital for further treatment.  A pulse oximeter should be used to gauge whether Flumazenil should be used. Consider using oxygen and bagging the individual if required.  The duration of action of flumazenil (half-life 52 minutes, duration of action 1-2 hours) is much shorter than the benzodiazepines; therefore, the respiratory function may recover and then deteriorate again.

 Flumazenil may precipitate: o a withdrawal syndrome in benzodiazepine-dependent individuals o convulsions in epileptics o arrhythmias in people who have taken cardiotoxic drugs.  Do NOT give flumazenil for mixed overdoses particularly combined tricyclic and benzodiazepine overdosage as convulsions and cardiac arrest may be precipitated.  Flumazenil should be used with caution in people with a history of seizures, head injury, hepatic impairment or chronic benzodiazepine use.

The aim of this sheet is to provide basic information to facilitate the safe use of flumazenil in an emergency situation. Please refer to the products SPC for more detailed information.

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 29 of 34

Appendix 5

Rapid Tranquillisation C36/CP11 – NICE Position Statement September 2015

Situation

The Trust rapid tranquillisation policy and clinical protocol were reviewed in light of the updated NICE guidelines NG10“Violence and aggression: short-term management in mental health, health and community settings” published in May 2015.

Background

The following areas were identified in which our current guidelines varied from the updated NICE guidelines – these questions were sent out to all consultant psychiatrists via the Medical Advisory Committee (MAC) and to senior nurses throughout the Trust:

1. Choice of Medication: The new NICE guideline does not include Olanzapine IM which is the 2nd line choice in our current guidelines - this was excluded by NICE because Olanzapine IM does not have a UK marketing authorisation (for commercial reasons) however NICE does not take into account the fact that it does have a pan European licence and therefore is licensed for use in the UK and is still readily available to import and there have been no issues with supply. This does have an effect on the cost although owing to its infrequent use this does not have a major budgetary impact overall. There is a substantial amount of evidence to support the use of IM Olanzapine in rapid tranquillisation. Olanzapine does not have the requirement which haloperidol has for a baseline ECG to be done or the same risk as haloperidol of severe extra pyramidal side effects. Should we maintain our current position of including Olanzapine IM as a treatment option in our Rapid Tranquillisation guidelines?

2. Prescribing of a single dose only: The new NICE guideline states - When prescribing medication for use in rapid tranquillisation, write the initial prescription as a single dose, and do not repeat it until the effect of the initial dose has been reviewed. Our current guidelines/prescription charts allow the prescription of repeated doses for one "episode" of rapid tranquillisation. If we were to follow the NICE guidelines this may cause delays in the prescription of a second dose causing increased suffering or risk. Should we maintain our current position of allowing repeated doses to be prescribed for an episode of rapid tranquillisation?

3. Inclusion of Promethazine: The new NICE guideline recommends that Haloperidol is given with Promethazine. Promethazine does not have a licence for use in rapid tranquillisation however is supported by a number of international studies. Should we update our guidelines in line with NICE to include the combined use of Promethazine with Haloperidol?

Assessment:

13 email responses were received from 12 consultants and 1 pharmacist. All unanimously agreed to keep Olanzapine as an option in our guidelines. 12 out of the 13 agreed that we should maintain our current position of allowing repeated doses to be prescribed for an episode of rapid tranquillisation however a number commented about the need to strengthen the requirement for a clinical review between doses. 12 out of the 13 agreed that we should update our guidelines in line with NICE to include the combined use of Promethazine with Haloperidol. The attendees of the DTC meeting in September were also unanimously in agreement with this.

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 30 of 34

Recommendation:

1. Our current position of including Olanzapine IM second line as a treatment option in our Rapid Tranquillisation guidelines should be maintained.

2. We should maintain our current position of allowing repeated doses to be prescribed for an episode of rapid tranquillisation, however a requirement to obtain a clinical review prior to giving a further dose will be added – this will involve the nurse contacting the medic who should ensure that all physical observations have been completed and that on the basis of this it is safe to proceed with a further dose.

3. We should update our guidelines in line with NICE to include the combined use of Promethazine with Haloperidol.

Decision:

The September 15 meeting of the Drugs and Therapeutics committee supported the recommendations above.

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 31 of 34

References

Andrezina R, Josiassen R, Marcus R et al (2006). Intramuscular aripiprazole for the treatment of acute agitation in patients with or : a double-blind, controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 188(3), 281-292

Battaglia J, Moss S, Rush J et al (1997) Haloperidol, Lorazepam or Both for Psychotic Agitation? A Multicenter, Prospective, Double-Blind, Emergency Department Study. American Journal of Emergency Medicine 15 3335-40

Bazire Stephen (2009) Psychotropic Drug Directory

Bieniek S, Ownby R, Penalver A et al (1998) A Double-Blind Study of Lorazepam versus the Combination of Haloperidol and Lorazepam in Managing Agitation. Pharmacotherapy 18 57-62

Currier G and Simpson G (2001)Risperidone Liquid Concentrate and Oral Lorazepam Versus Intramuscular Haloperidol and Intramuscular Lorazepam for Treatment of Psychotic Agitation. Journal of Clinical Psychiatry 62 153-157

Dickinson T et al (2009) Managing aggression and violence using rapid tranquillisation. Nursing Standard. 24(7), 40-51

Dubin, W. R. (1988) Rapid Tranquillisation: antipsychotics or benzodiazepines? Journal of Clinical Psychiatry, 49, 5-11.

Holmes, C. L., Simmons, H., Pilowsky, L. S. (2001) Rapid tranquillisation. In Psychiatric intensive care (eds M. D. Beer, S. Pereira, & C. Paton), pp. 41-58. London.

Huf, G., Coutinho, E.S.F. and Adams, C.E. 2002 TREC-Rio trial: a RCT for rapid tranquillisation for agitated patients in emergency psychiatric rooms. BMC Psychiatry 2:11

Huf G, Alexander J, Allen M, Raveendran N. 2009. Haloperidol plus promethazine for - induced aggression (review). The Cochrane Library 2009 Issue 3

Huf G TREC Collabrotive group. 2003 Rapid Tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 327(7417): 708- 13

Innes J and Iyeke L. 2011. A review of the practice and position of monitoring in today’s rapid tranquilisation protocols. Journal of Psychiatric Intensive Care. 8 (1), 15-24

Jones, B., Taylor, C. C., and Meehan, K. (2001) The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. Journal of Clinical Psychiatry, 62, 22-24.

Karagianis J, Dawe I, Thakur A et al (2001) Rapid Tranquillisation With Olanzapine in Acute Psychosis:A Case Series Journal of Clinical Psychiatry 12-16

Karagianis, J. L., Dawe, I. C., Thakur, A., et al (2001) Rapid tranquillisation with olanzapine in acute psychosis: a case series. Journal of Clinical Psychiatry, 6, 12-16.

Kerr, I. B. and Taylor, D. (1997) Acute disturbed or violent behaviour: principles of treatment. Journal of Psychopharmacology, 11, 271-277. CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 32 of 34

Kinon B, Rotelli M, Gilmore J et al. (2003) The Efficacy of Olanzapine and Adjunctive Lorazepam to Treat Acute Behavioural Agitation in Schizophrenia

Martel M, Sterzinger A, Miner J, Clinton J, Biros M. (2005). Management of acute undifferentiated agitation in the emergency department: A randomised double-blind trial of , zisprasidone, and midazolam. Academic Emergency Medicine. 12(12): 1167-1173.

McAllister-Williams, R. H. and Ferrier, I. N. (2002) Rapid tranquillisation: time for a reappraisal of options for parenteral therapy. The British Journal of Psychiatry, 180, 485-489.

NICE (2005) Clinical Guidelines for the Short Term Management of Disturbed/ violent behaviour in psychiatric in-patient settings and accident and emergency settings. CG25

NICE (2007) Clinical Guidelines for antenatal and postnatal mental health. CG45

NICE (May 2015) Violence and aggression: short-term management in mental health, health and community settings. CG10

Nishiyama T, Matsukawa T, Hanaoka K. 1998. The Effects of age and gender on optimal premedication dose of intramuscular midazolam. 86: 1103-1108.

Nobay, F., Simon, B., Levitt, A. and Dresden, G.M. 2004 A Prospective, DB, RCT of midazolam vs, Haloperidol vs. lorazepam in the chemical restraint of violent and severely agitated patients. Academic Emergency Medicine 11(7) 744-749

Paton, C (2002) Benzodiazepines and disinhibition: a review. Psychiatric Bulletin, 26, 460-462.

Pereira S et al (2006) Treatment of acute behavioural disturbance: a UK national survey of rapid tranquillisation. Journal of Psychiatric Intensive Care, 1, 84-88

Pratt P et al. (2008) Establishing gold standard approaches to rapid tranquillisation: A review and discussion of the evidence on the safety and efficacy of medications currently used. Journal of psychiatric intensive care, 4, 43-57

Taylor D, Paton C, Kapur S (2009) The Maudsley Prescribing Guidelines 10th Edition: Acutely disturbed or violent behaviour pg 417-422.

Taylor D, Paton C, Kapur S (2012) The Maudsley Prescribing Guidelines 11th Edition: Acutely disturbed or violent behaviour pg 531-538

The electronic Medicines Compendium (eMC)

Tran-Johnson T et al. (2007) Efficacy and Safety of intramuscular aripiprazole in patients with acute agitation: a randomised, double-blind, placebo-controlled trial. Journal clin Psychiatry 68(1), 111-119

TREC Collaborative Group 2003 Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam vs. haloperidol plus promethazine. British Medical Journal 327 708-711

Wright, Padraig, Birkett, Martin, David, Stacy R., et al (2001) Double-Blind, Placebo-Controlled Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in the Treatment of Acute Agitation in Schizophrenia. American Journal of Psychiatry, 158, 1149-1151

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 33 of 34

Acknowledgements

Guidelines from other Trusts

Rapid Tranquillisation; South West Region Guidelines (2004)

Central and North West London Mental Health NHS Trust (2003)

Norfolk Mental Healthcare NHS Trust (2003)

North East London Mental Health Trust

South West Yorkshire Mental Health NHS Trust

Sussex Partnership NHS Foundation Trust The RT policy (2009)

Derbyshire Mental Health services NHS Trust Guidelines for the management of the acutely disturbed patient.

Coventry and Warwickshire Partnership Trust. Medication for RT and challenging behaviour.

CP11 - Protocol for Rapid Tranquillisation Approved by Medicines Safety Committee: July 2021 Review Date: July 2024 Page 34 of 34